Examples of such trials are the HOVON 150 (for IDH1/2 mutated AML, NCT03839771) and HOVON 156 (for FLT3 mutated AML, NCT04027309), in which fitness for intensive treatment, and not age itself, defines eligibility for these trials. This evidence concerns the gene FLT3 and acute myeloid leukemia.